[1] Brenner DA,Alcorn JM. Therapy for hepatic fibrosis. Semin Liver Dis,1990,10（1）:75-83.
[2] Lee YA,Wallace MC,Friedman SL. Pathobiology of liver fibrosis:a translational success story. Gut,2015,64（5）:830-841.
[3] Schiff E,Simsek H,Lee WM,et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol,2008,103（11）:2776- 2783.
[4] Chang TT,Liaw YF,Wu SS,et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology,2010,52（3）:886-893.
[5] Marcellin P,Gane E,Buti M,et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study. Lancet,2013,381（9865）: 468-475.
[6] Hernandez-Gea V,Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol,2011,6:425-456.
[7] 韩经寰,李凤阁. 强肝软坚汤治疗肝硬变的实验研究. 中华医学杂志,1979,59（10）:577.
[8] 中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南. 中国中西医结合杂志,2006,26（11）:1052-1056.
[9] Liu P,Hu YY,Liu C,et al. Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B. World J Gastroenterol,2005,11（19）:2892-2899.
[10] Hassanein T,Box TD,Tong MJ,et al. A phase II,randomized, placebo-controlled,double-blind,multicenter study to assess the antifibrotic activity of Fuzheng Huayu in chronic hepatitis C patients with hepatic fibrosis. Hepatol Int,2014,8:S308-S309.
[11] Liu C,Hu Y,Xu L,et al. Effect of Fuzheng Huayu formula and its actions against liver fibrosis. Chin Med,2009,4（1）:12-22.
[12] 吴秀美,曾常春. 鳖甲软肝丸治疗慢性乙型肝炎肝纤维化患者的临床观察. 中药新药与临床药理,2003,14（3）:203-205.
[13] 周光德,李文淑,赵景民,等. 复方鳖甲软肝片抗肝纤维化机制的临床病理研究. 解放军医学杂志,2004,29（7）:563-564.
[14] 黄志巧. 安络化纤丸抗肝纤维化疗效的Meta分析. 中国药物评价,2015,32（1）:41-44.
[15] 杨柳明,徐克成,赵延龙,等. 强肝胶囊治疗慢性乙型肝炎肝纤维化的临床病理研究. 胃肠病学和肝病学杂志,2001,3（10）:247-249.
[16] 尹珊珊,王宝恩,王泰龄,等. 复方861治疗慢性乙型肝炎肝纤维化与早期肝硬化的临床研究. 中华肝脏病杂志,2004,12（8）:467-470.
[17] 唐礼瑞,郭涛,陶艳艳,等. 扶正化瘀胶囊联合核苷（酸）类药物治疗慢性乙型肝炎肝纤维化的初步系统评价. 中西医结合肝病杂志,2013,23（3）:183-187.
[18] 刘金旭,陈文梅. IFN-α2b联合扶正化瘀胶囊治疗慢性乙型肝炎疗效观察. 肝脏,2012,17（2）:140-142.
[19] 段雪琳,黎桂玉,李树民,等. 复方鳖甲软肝片联合恩替卡韦对慢性乙型肝炎血清肝纤维化标志物影响的Meta分析. 中国医院药学杂志,2015,35（19）:1-4.
[20] 贺娟,徐贵丽. 复方鳖甲软肝片联合阿德福韦酯治疗慢性乙型肝炎肝纤维化疗效的系统评价. 中国药房,2010,21（44）:4198-4201.
[21] 袁剑峰,江应安,张翠芳,等. 抗病毒药物联合安络化纤丸治疗乙型肝炎肝硬化疗效 Meta 分析. 传染病信息,2013,26（5）:288-291.
[22] 赵韦,赵志敏,王峥涛,等. 活血化瘀类方抗肝纤维化疗效比较. 中药药理与临床,2012,28（3）:15-18.
[23] 赵志敏,余慧颖,彭渊,等. 清热活血类方剂防治CCl4小鼠肝纤维化的药效比较. 中国中药杂志,2012,37（12）:1804-1808.
[24] Schuppan D,Pinzani M. Anti-fibrotic therapy:lost in translation J Hepatol,2012,56 （Suppl 1）:S66-74.
[25] Weng HL,Liu Y,Chen JL,et al. The etiology of liver damage imparts cytokines transforming growth factor beta1 or interleukin-13 as driving forces in fibrogenesis. Hepatology,2009,50（1）:230-243.
[26] Torok NJ,Dranoff JA,Schuppan D,et al. Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference,Chicago,June 2014. Hepatology,2015,62（2）:627-634. |
